Quality of Erection Study

NCT00159900

Last updated date
Study Location
Pfizer Investigational Site
Belo Horizonte, MG, 30130-008, Brazil
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Erectile Dysfunction
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-55 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male subjects aged 18-55

- Documented clinical diagnosis of erectile dysfunction confirmed by an IIEF-EF Domain score of less than or equal to 25. (If the subject scores greater than 25 on the IIEF-EF Domain, screening procedures should be terminated.)

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Subjects who have been treated with more than 6 doses of sildenafil citrate or any
other phosphodiesterase type 5 (PDE-5) inhibitor such as vardenafil or tadalafil for
erectile dysfunction [Note: subjects should not have taken any PDE-5 inhibitors within
4 weeks prior to the date of screening]

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Erectile DysfunctionA Relative Bioavailability Study Between Two Formulations Of Sildenafil Citrate
NCT00904748
  1. Braganca Paulista, SP
Male
18 Years+
years
MULTIPLE SITES
Erectile DysfunctionA Study to Evaluate Self-esteem and Relationships in Males With Erectile Dysfuntion
NCT00648596
  1. Oulu,
  2. Tampere,
  3. Turku,
  4. Clermont Ferrand,
  5. Le Kremlin Bicentre,
  6. Lyon Cedex 03,
  7. MARSEILLE Cedex 20,
  8. Neuilly-sur-seine,
  9. NICE Cedex 01,
  10. Nimes,
  11. Toulouse,
  12. Bari,
  13. Catania,
  14. Gallarate (va),
  15. Modena,
  16. Padova,
  17. Roma,
  18. Siena,
  19. Torino,
  20. Krakow,
  21. Lodz,
  22. Lublin,
  23. Olsztyn,
  24. Szczecin,
  25. Warszawa,
  26. Moscow, Russia
  27. Moscow, Russia
  28. Moscow, Russia
  29. Moscow, Russia
  30. Moscow, Russia
  31. Novosibirsk, Russia
  32. Rostov-on-don, Russia
  33. St. Petersburg, Russia
  34. St. Petersburg, Russia
  35. Barnaul,
  36. Ekaterinburg,
  37. Moscow,
  38. Moscow,
  39. Moscow,
  40. Nizhny Novgorod,
  41. Novosibirsk,
  42. Saint-Petersburg,
  43. Saint-Petersburg,
  44. San Juan, Alicante
  45. Barakaldo, Vizcaya
  46. Barcelona,
  47. Madrid,
  48. Madrid,
  49. Madrid,
  50. Valencia,
  51. Valencia,
  52. Zaragoza,
  53. Karlshamn,
  54. Malmo,
  55. Skovde,
  56. Stockholm,
  57. Varnamo,
  58. Vastervik,
  59. Bodelwyddan, Denbighshire
  60. South Yorkshire, Dn1 2et
  61. Belmont, Durham
  62. Blackpool, Lancashire
  63. Urmston, Manchester
  64. Ashford, Middlesex
  65. Nr Lichfield, Staffordshire
  66. Addlestone, Surrey
  67. Taunton, Ta1 5da
Male
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Quality of Erection Study
Official Title  ICMJE A Multicenter, Parallel Group Flexible Dose Study With A Double Blind, Randomized, Placebo Controlled Phase And An Open-Label Phase To Evaluate The Quality Of Erections In Men With Erectile Dysfunction Treated With Sildenafil Citrate
Brief Summary The study objective is to evaluate the effect that sildenafil citrate has on the hardness of erections in males with erectile dysfunction, based on subject responses to question 5 on the Event Log (hardness of erection) as measured at the end of double blind treatment (week 6).
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Erectile Dysfunction
Intervention  ICMJE Drug: Sildenafil Citrate
Study Arms  ICMJE Not Provided
Publications * Kaminetsky JC, Stecher V, Tseng LJ. Quality of erections by age group in men with erectile dysfunction. Int J Clin Pract. 2017 Oct;71(10). doi: 10.1111/ijcp.12976. Epub 2017 Sep 11.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE
 (submitted: September 8, 2005)
300
Original Enrollment  ICMJE Same as current
Study Completion Date  ICMJE January 2006
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male subjects aged 18-55
  • Documented clinical diagnosis of erectile dysfunction confirmed by an IIEF-EF Domain score of less than or equal to 25. (If the subject scores greater than 25 on the IIEF-EF Domain, screening procedures should be terminated.)

Exclusion Criteria:

  • Subjects who have been treated with more than 6 doses of sildenafil citrate or any other phosphodiesterase type 5 (PDE-5) inhibitor such as vardenafil or tadalafil for erectile dysfunction [Note: subjects should not have taken any PDE-5 inhibitors within 4 weeks prior to the date of screening]
Sex/Gender  ICMJE
Sexes Eligible for Study:Male
Ages  ICMJE 18 Years to 55 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Brazil,   Germany,   Italy,   Poland,   Turkey
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00159900
Other Study ID Numbers  ICMJE A1481222
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date April 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP